3月20日上午,和黄医药举办2024全年业绩简报会。谈及公司的中期展望时,相关负责人表示,利用充裕的现金储备,收购具有中国商业化潜力的产品。对于收购计划,和黄医药负责人称,公司刚刚开始探索,目前还没有具体的时间点等信息。基本上,公司是比较开放的态度,优先的目标是跟公司现有产品有协同作用的产品,“一些比较后期的产品,短期能够上市的创新肿瘤或免疫方面的产品”。上述负责人强调,收购的产品来自国内还是国外...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.